Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum membrane Multi-pass membrane protein |
Domain |
PF05208 ALG3 protein |
Function |
Adds the first Dol-P-Man derived mannose in an alpha-1,3 linkage to Man5GlcNAc2-PP-Dol. |
Biological Process |
GO:0006486 protein glycosylation GO:0006488 dolichol-linked oligosaccharide biosynthetic process GO:0006490 oligosaccharide-lipid intermediate biosynthetic process GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0043413 macromolecule glycosylation GO:0070085 glycosylation GO:0097502 mannosylation |
Molecular Function |
GO:0000030 mannosyltransferase activity GO:0000033 alpha-1,3-mannosyltransferase activity GO:0016757 transferase activity, transferring glycosyl groups GO:0016758 transferase activity, transferring hexosyl groups GO:0052925 dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase activity |
Cellular Component | - |
KEGG |
hsa00510 N-Glycan biosynthesis hsa01100 Metabolic pathways |
Reactome |
R-HSA-446203: Asparagine N-linked glycosylation R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ALG3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ALG3 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ALG3 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ALG3 in various data sets.
|
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ALG3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ALG3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ALG3. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ALG3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ALG3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ALG3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ALG3 |
Name | ALG3, alpha-1,3- mannosyltransferase |
Aliases | NOT56L; Not56; CDGS4; D16Ertd36e; carbohydrate deficient glycoprotein syndrome type IV; dol-P-Man:Man(5)GlcN ...... |
Chromosomal Location | 3q27.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ALG3 collected from DrugBank database. |
There is no record. |